A Favorable Response to Levetiracetam in a Patient with Metastatic Adenoid Cystic Carcinoma

Adenoid cystic carcinoma (ACC) is a rare cancer, and there are no standard-of-care treatments for patients with metastatic ACC. We herein report a patient with lung metastasis of ACC who achieved a favorable response to levetiracetam. A 52-year-old Japanese man was admitted to our hospital because of multiple lung metastases of ACC. We performed first-line chemotherapy with cisplatin plus gemcitabine, and subsequently oral S-1 as second-line chemotherapy, which resulted in disease progression. The patient developed symptomatic epilepsy and received levetiracetam (250 mg twice daily). At five months after the initiation of levetiracetam, chest computed tomography showed regression of the metastatic lung lesions.

[1]  G. Burton,et al.  Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam , 2016, BMJ Case Reports.

[2]  A. Ho,et al.  Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. , 2011, The Lancet. Oncology.

[3]  J. Reijneveld,et al.  Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex. , 2010, Neuro-oncology.

[4]  D. Tu,et al.  A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer , 2010, Cancer.

[5]  D. Lacombe,et al.  Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). , 2008, European journal of cancer.

[6]  B. Nilsson,et al.  Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. , 2007, Endocrine-related cancer.

[7]  R. Dodd,et al.  Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. , 2006, Oral oncology.

[8]  G. Gademann,et al.  Effects of imatinib mesylate on adenoid cystic carcinomas. , 2005, Anticancer research.

[9]  E. Lamont,et al.  Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Miyoshi,et al.  [Successful treatment of multiple pulmonary metastases of adenoid cystic carcinoma of the external auditory meatus with TS-1]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

[11]  H. Goepfert,et al.  Adenoid cystic carcinoma of the head and neck: Predictors of morbidity and mortality , 1999 .

[12]  M. Levitt,et al.  A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. , 2007, Oral oncology.

[13]  A. Wiener,et al.  Adenoid cystic carcinoma. , 1977, The New York state dental journal.